Bank of New York Mellon Corp Has $857,000 Stock Holdings in Shattuck Labs, Inc. (NASDAQ:STTK)

Bank of New York Mellon Corp lifted its holdings in shares of Shattuck Labs, Inc. (NASDAQ:STTK) by 209.7% in the second quarter, according to its most recent filing with the SEC. The firm owned 222,034 shares of the company’s stock after acquiring an additional 150,340 shares during the period. Bank of New York Mellon Corp’s holdings in Shattuck Labs were worth $857,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. SG Americas Securities LLC lifted its position in shares of Shattuck Labs by 4.8% during the 1st quarter. SG Americas Securities LLC now owns 39,377 shares of the company’s stock worth $352,000 after buying an additional 1,788 shares during the period. Cannon Global Investment Management LLC acquired a new position in Shattuck Labs during the first quarter worth $91,000. Virtu Financial LLC bought a new position in shares of Shattuck Labs during the first quarter valued at $113,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Shattuck Labs in the 1st quarter valued at $174,000. Finally, Pinnacle Associates Ltd. grew its holdings in shares of Shattuck Labs by 13.9% in the 1st quarter. Pinnacle Associates Ltd. now owns 521,246 shares of the company’s stock worth $4,660,000 after purchasing an additional 63,800 shares during the last quarter. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Shattuck Labs Trading Up 1.1 %

Shares of NASDAQ STTK opened at $3.74 on Friday. Shattuck Labs, Inc. has a 1-year low of $1.33 and a 1-year high of $11.76. The company has a 50-day moving average of $3.72 and a two-hundred day moving average of $6.39. The company has a market cap of $178.51 million, a PE ratio of -1.94 and a beta of 1.72.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.01). The firm had revenue of $1.61 million for the quarter, compared to analyst estimates of $0.50 million. Shattuck Labs had a negative return on equity of 68.65% and a negative net margin of 2,067.99%. The firm’s revenue for the quarter was up 704.5% on a year-over-year basis. As a group, equities research analysts forecast that Shattuck Labs, Inc. will post -1.72 earnings per share for the current year.

Insider Activity

In other news, CEO Taylor Schreiber acquired 14,400 shares of the stock in a transaction that occurred on Wednesday, June 26th. The stock was purchased at an average cost of $3.47 per share, for a total transaction of $49,968.00. Following the completion of the transaction, the chief executive officer now directly owns 34,502 shares in the company, valued at $119,721.94. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 10.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Citigroup cut their price target on shares of Shattuck Labs from $9.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, August 15th. BTIG Research downgraded Shattuck Labs from a “buy” rating to a “neutral” rating in a report on Monday, June 17th. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Shattuck Labs in a research report on Tuesday, August 27th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Shattuck Labs in a research report on Friday, August 2nd.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.